# A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-M23, a CAR-T Cell Therapy Targeting MSLN in Patients With Relapsed and Refractory Epithelial Ovarian Cancer

> **NCT04562298** · PHASE1 · TERMINATED · sponsor: **Shanghai East Hospital** · enrollment: 15 (actual)

## Conditions studied

- Epithelial Ovarian Cancer

## Interventions

- **BIOLOGICAL:** LCAR-M23 cells

## Key facts

- **NCT ID:** NCT04562298
- **Lead sponsor:** Shanghai East Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-10-21
- **Primary completion:** 2022-06-07
- **Final completion:** 2022-06-07
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Both the sponsors and collaborator are considering terminating the study.
- **Last updated:** 2022-08-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04562298

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04562298, "A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-M23, a CAR-T Cell Therapy Targeting MSLN in Patients With Relapsed and Refractory Epithelial Ovarian Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04562298. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*